echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Betta Pharmaceuticals accepted the application for registration of first-line treatment indication drugs for Ensatinib Hydrochloride

    Betta Pharmaceuticals accepted the application for registration of first-line treatment indication drugs for Ensatinib Hydrochloride

    • Last Update: 2021-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 13, Betta Pharmaceuticals announced that it had received the "Notice of Acceptance" (acceptance number: CXHS2101028 country, CXHS2101029 country) issued by the State Food and Drug Administration, and the company declared Ensatinib Hydrochloride Capsules (Bemena ®) The application for marketing authorization for "applicable to the treatment of patients with anaplastic lymphoma kinase (ALK) positive locally advanced or metastatic non-small cell lung cancer (NSCLC)" has been accepted by the State Food and Drug Administration


    Ensatinib Hydrochloride Capsules is a new generation of potent and highly selective ALK inhibitors.


    The drug registration application submitted this time is an application for new indications for Ensatinib


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.